GU Cancers 2024 | [68Ga]Ga-DPI-4452, a novel CA IX-targeting peptide, in metastatic ccRCC
Michael Hofman, FRACP, MBBS, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses results from a Phase I trial (NCT05706129) of [68Ga]Ga-DPI-4452, a cyclic peptide targeting carbonic anhydrase IX (CA IX), in patients with unresectable metastatic clear cell renal cell carcinoma (ccRCC). The radiolabeled peptide exhibited exceptional imaging characteristics without significant toxicity and PET-CT scans revealed rapid and sustained tumor uptake, particularly in lesions undetectable by contrast-enhanced CT. Dosimetry estimates indicated low absorbed doses in critical organs, supporting its safety profile. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
So at ASCO GU this year we present the results of the first three patients imaged with a small molecule targeting CA IX which is carbonic anhydrase nine in patients with clear cell renal cancer. And we saw really exceptional uptake within the tumors in these three patients with a very good imaging profile which means very low background activity. So for those not aware of this target, this is expressed on the cell surface of a number of tumors, including renal cell cancer...
So at ASCO GU this year we present the results of the first three patients imaged with a small molecule targeting CA IX which is carbonic anhydrase nine in patients with clear cell renal cancer. And we saw really exceptional uptake within the tumors in these three patients with a very good imaging profile which means very low background activity. So for those not aware of this target, this is expressed on the cell surface of a number of tumors, including renal cell cancer. In this study there is another cohort with pancreatic cancer and colorectal cancer which has not yet been reported. But these were the first three patients imaged at our institution with clear cell renal cancer with metastatic disease. And we saw extremely high uptake on a PET scanner. We can measure this using the SUV or standardized uptake value. And we saw numbers above 100 in all three patients. So this is really quite extraordinary uptake. So it looks like it’s a very promising tracer for imaging. And this was labeled to gallium 68 similar to PSMA in prostate cancer. And there’s also a phase of the study labeled to lutetium 177 for therapy. That has not commenced yet. But it looks like that this may be a very promising tracer, both for imaging and for treatment.
Read more...
